HLB bioStep Non-Registered Director Myungjin Kim Reduces Stake from 0.34% to 0.10% via Open-Market Sales... Limited Impact on Share Price
HLB bioStep non-registered director Myungjin Kim sold a total of 40,781 shares (average price approx. 4,039 KRW) from May 21 to 27, 2026, reducing his stake from 0.34% to 0.10%.
The sales are presumed to be for personal liquidity needs; no pre-arranged trading plan was reported.
He also bought 200 shares at an average price of 4,158 KRW during the same period, but the repurchase is negligible relative to the total reduction.
This change represents only 0.24% of total outstanding shares (17.43 million), thus direct price impact is limited.
[AI Comprehensive Analysis]Insider sales of a small stake can be a negative signal for investor sentiment, but the actual impact on enterprise value is minimal due to the tiny size. Investors should note this for share price outlook but avoid overinterpretation.
KOSDAQ Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders